Ohr Pharmaceutical, Inc. S-4


 


Exhibit 10.15 


 


***
Text Omitted and Filed Separately


Confidential
Treatment Requested


Under
17 C.F.R. §§ 200.80(c)


 


LICENSE
AGREEMENT



Carnegie Mellon University – NeuBase Therapeutics, Inc.


 


This
Agreement (hereinafter “this Agreement”) entered into as of 17th day of December, 2018 (“Effective Date”)
by and between Carnegie Mellon University, a Pennsylvania not-for- profit corporation, having a principal place of business at
5000 Forbes Avenue, Pittsburgh, PA (“Carnegie Mellon”) and NeuBase Therapeutics, Inc. a Delaware corporation, having
a principal place of business at 2730 Sidney Street, Suite 300, Pittsburgh, PA 15203 (“Licensee”).


 


Witnesseth


 


Whereas,
Carnegie Mellon owns certain rights in certain technology relating to the detection and treatment of disease and is interested
in licensing same; and,


 


Whereas,
Licensee desires to acquire rights in and to that technology upon the terms and conditions herein set forth;


 


Now
Therefore, in consideration of the mutual covenants contained herein and intending to be legally bound hereby, the parties
agree as follows:


 


1.
Certain Definitions (“Defined Terms”)


 


1.1.
“Patent(s)” shall mean any patent application, including any continuation, continuation- in-part, divisional
or modification filed in the U.S. or in any other country and any patent claiming priority therefrom or reissue thereof, which
issues to Carnegie Mellon and specifically claims any of the Licensed Technology in existence on the Effective Date, and the patents
and patent applications identified in Attachment A,.


 


1.2.
“Licensed Technology” or “Technology” shall mean (a) the technology described in Attachment
A on an “as is” basis on the Effective Date, and (b) Patents.


 


1.3.
“Licensed Product” or “Product” shall mean any product and/or service which constitutes,
is based on, incorporates or utilizes, wholly or in part, Licensed Technology, or the manufacture, use, sale, offer for sale,
or importation of which would infringe any claim of a Patent.


 


1.4.
“Year” refers to contract years of this Agreement, i.e. a twelve (12) month period starting with the date (or
anniversary) of the Effective Date.


 


1.5.
“Fiscal Quarter” or “Quarter” shall refer to the normal quarterly accounting periods of
Licensee; if Licensee does not have normal quarterly accounting periods, then a “Fiscal Quarter” shall mean the calendar
three months period commencing with January of each year.


 


1.6.
“Dispose” or “Disposition” shall mean the use, sale, lease or other transfer.


 


1.7.
“Revenue” shall mean the U.S. Dollar value of all consideration invoiced by Licensee and/or its Sublicensees
for the Disposition of Licensed Product(s), other than the Disposition of Licensed Product(s) to Sublicensees and Affiliates for
the purpose of conducting research on behalf of Licensee.


 






     


     


    

 


1.8.
“Affiliate” shall mean any entity that, directly or indirectly, through one or more intermediates, controls,
is controlled by, or is under common control with Licensee. For the purpose of this definition, control means the direct or indirect
ownership of at least fifty percent (50%) of (i) the stock shares entitled to vote for the election of directors or (ii) ownership
interest.


 


1.9.
“Net Sales” shall mean the total Revenues, less the total of all of the following deductions:


 


(a)
customary and reasonable trade discounts actually allowed, refunds, returns and recalls according to generally accepted accounting
principles ; 


(b)
sales tariffs, duties, and/or taxes, including but not limited to V.A.T. and/or use taxes, based on sales of the Licensed Products
according to generally accepted accounting principles, but not including taxes when assessed on incomes derived from such sales; 


(c)
customary and reasonable freight, shipping, and outbound transportation prepaid or allowed according to generally accepted accounting
principles; 


(d)
deductions for bad debt according to generally-accepted accounting principles; and 


(e)
amounts allowed or credited on returns according to generally accepted accounting principles.


 


No
deduction shall be made for commissions paid to individuals or entities whether they be independent sales agents or persons regularly
engaged or employed by Licensee and/or a sublicensee.


 


1.10.
“Royalties” shall mean royalties which are calculated as a percentage of Net Sales and will be payable by Licensee
to Carnegie Mellon under the provisions of this Agreement.


 


1.11.
“Sublicense Fees” shall mean any consideration realized by Licensee from a sublicensee, excluding amounts payable
to Licensee by a sublicensee on account of Net Sales.


 


1.12.
“Dollar”, “U.S. Dollar” and “$ U.S.” shall mean lawful money of the United
States of America.


 


1.13.
“Prime Rate” shall mean the prime rate in the Wall Street Journal newspaper in its “Money Rates”
column on the Effective Date.


 


1.14.
“Field of Use” shall mean all uses related to the diagnosis, monitoring, and treatment of human and animal
health including but not limited to therapeutics and diagnostics in any indication, and uses as research tools.


 


1.15.
“Split Agreement” shall mean the split agreement between Carnegie Mellon and the Creators of Licensed Technology.


 


1.16.
“Creators” shall mean the thirteen (13) persons identified in the Split Agreement, namely [* * *].


 






     


     


    

 


1.17.
“Qualified IPO” shall mean an underwritten initial public offering by Licensee under the Securities Act of
1933, as amended, for its own account pursuant to a registration statement on Form S-l or its equivalent where the valuation of
Carnegie Mellon’s initial eight and two tenths percent (8.2%) interest in Licensee immediately preceding such offering (and
without giving effect thereto) is at least Four Million Dollars (U.S. $4,000,000).


 


1.18.
“Qualified Sale” shall mean (i) a cash merger of Licensee with another entity in which, based upon the aggregate
cash consideration delivered to Licensee’s Owners, the valuation of Carnegie Mellon’s eight and two tenths percent
(8.2%) equity interest in Licensee is at least Four Million Dollars (U.S. $4,000,000) or (ii) a sale of substantially all the
assets of Licensee to a third party in which, based upon the net proceeds from such sale distributed to the Owners of Licensee,
the valuation of Carnegie Mellon’s eight and two tenths percent (8.2%) equity interest in Licensee is at least Four Million
Dollars (U.S. $4,000,000).


 


1.19.
“Change of Control Event” shall mean (i) a Qualified IPO, or (ii) a Qualified Sale.


 


1.20.
“Shares” shall mean any of the following held by an Owner: (a) any limited liability company (“LLC”)
units, capital stock or other equity interest in the Licensee; (b) any warrants, options or other rights to subscribe for or to
acquire, directly or indirectly, LLC units, capital stock or other equity interest in the Licensee, whether or not then exercisable
or convertible; (c) any LLC units, stock, notes, other securities, or other equity interest which is convertible into or exchangeable
for, directly or indirectly, LLC units, capital stock, or other equity interest in Licensee, whether or not then convertible or
exchangeable; and (d) any equity securities issued or issuable directly or indirectly with respect to the securities referred
to in clauses (a), (b) and (c) above by way of distribution, stock dividend or stock split or in connection with a combination
of LLC units, capital stock, or other equity interest, recapitalization, merger, consolidation or other reorganization. As to
any particular securities constituting Shares, such securities will cease to be Shares when they have been transferred in a public
sale.


 


1.21.
“Owner” shall mean owner of Shares in Licensee.


 


2.
License Grant


 


2.1.
Carnegie Mellon hereby grants to Licensee, and Licensee hereby accepts, an exclusive, world-wide right to the Patents and the
Licensed Technology to make, have made, use, sell, offer to sell, import, and otherwise Dispose of Licensed Products within the
Field of Use.


 


2.2.
Carnegie Mellon hereby grants to Licensee the right to sublicense the Patents and the Technology without the right to further
sublicense except (a) Licensee’s sublicensee (a “Sublicensee”) may sublicense to Sublicensee’s customers,
distributors, and/or resellers the Licensed Technology in the ordinary course of business to the extent necessary for use and
practice of the Licensed Product Disposed of by Sublicensee to said customers, distributors, and/or resellers or to Sublicensee’s
suppliers manufacturing Licensed Products for or on behalf of Sublicensee to the extent necessary to manufacture Licensed Products
for or on behalf of Sublicensee within the Field of Use; or (b) with the prior written agreement of Carnegie Mellon within the
Field of Use.


 






     


     


    

 


(1)
Any sublicenses granted by Licensee and Sublicensee to any person or entity, other than customers in the ordinary course of business
and to the extent necessary for the use and practice of the Licensed Products Disposed of by Licensee to said customer, must provide
that the obligations to Carnegie Mellon under this Agreement are met and will be conditioned upon and subject to the following
conditions:


 


(a)
Licensee will provide to Carnegie Mellon a copy of each sublicense within sixty (60) days of the date of each such sublicense
has been entered into subject to redaction of confidential commercial terms that are not Revenue related.


 


(b)
Further, any such sublicense entered into by Licensee will expressly include the following provisions for the benefit of Carnegie
Mellon:


 


THE
INTELLECTUAL PROPERTY, TECHNOLOGY, INFORMATION, PRODUCTS AND/OR MATERIALS FURNISHED OR MADE AVAILABLE HEREUNDER ARE FURNISHED
OR MADE AVAILABLE, IN WHOLE OR IN PART, BY NEUBASE THERAPEUTICS, INC UNDER A LICENSE FROM CARNEGIE MELLON UNIVERSITY (“CARNEGIE
MELLON”). CARNEGIE MELLON MAKES NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, AS TO ANY MATTER INCLUDING, BUT
NOT LIMITED TO, WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, EXCLUSIVITY OR RESULTS OBTAINED FROM USE OF ANY
INTELLECTUAL PROPERTY, TECHNOLOGY, INFORMATION, PRODUCTS AND/OR MATERIALS FURNISHED OR PROVIDED. FURTHER, CARNEGIE MELLON MAKES
NO WARRANTIES OF ANY KIND WITH RESPECT TO FREEDOM FROM PATENT, TRADEMARK, OR COPYRIGHT INFRINGEMENT, OR THEFT OF TRADE SECRETS
AND DOES NOT ASSUME ANY LIABILITY HEREUNDER OR OTHERWISE FOR ANY INFRINGEMENT OF ANY PATENT, TRADEMARK, OR COPYRIGHT ARISING FROM
THE USE OF THE INTELLECTUAL PROPERTY, TECHNOLOGY INFORMATION, PRODUCTS AND/OR MATERIALS.


 


CARNEGIE
MELLON SHALL NOT BE LIABLE TO [INSERT NAME OF SUBLICENSEE] OR ANY THIRD PARTY FOR ANY REASON WHATSOEVER ARISING OUT OF OR RELATING
TO THIS [INSERT NAME OF SUBLICENSE], INCLUDING ANY OF THE INTELLECTUAL PROPERTY, TECHNOLOGY, INFORMATION, PRODUCTS AND/OR MATERIALS
FURNISHED OR MADE AVAILABLE HEREUNDER, FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES SUCH AS LOSS OF PROFITS OR INABILITY TO
USE SAID INTELLECTUAL PROPERTY, TECHNOLOGY, INFORMATION, PRODUCTS AND/OR MATERIALS OR ANY APPLICATIONS OR DERIVATIONS THEREOF,
EVEN IF CARNEGIE MELLON AND/OR ANY OF ITS LICENSEES HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.


 


[insert
name of sublicensee] shall defend, indemnify and hold harmless Carnegie Mellon, its trustees, officers, employees, attorneys and
agents from and against all claims or demands made against any one or more them (and any related losses, expenses and costs, including
attorneys’ fees and expenses) arising out of or relating to [insert name of sublicensee]’s use or disposition of or
act or omission regarding, the intellectual property, technology, information, products or materials furnished or provided hereunder
and/or any goods or services which are based on or utilize any of the foregoing in whole or in part including but not limited
to, any claims of product liability, personal injury (including, but not limited to, death), damage to property or violation of
any laws or regulations including, but not limited to, claims of active or passive negligence.


 






     


     


    

 


Carnegie
Mellon is an express third party beneficiary of this [insert name of sublicense].


 


2.3.
Carnegie Mellon shall have the right to use the Patents and Licensed Technology for Carnegie Mellon research, educational, and
academic purposes.


 


2.4.
Nothing in this Agreement shall restrict non-commercial academic research or other not- for-profit scholarly activities, which
are undertaken at a nonprofit or governmental institution in the Field of Use and/or in the area of Licensed Technology and/or
any other areas. It is understood that this term does not restrict Licensee from enforcing the Patents against a commercial entity
or commercial activity.


 


2.5.
Licensee and any sublicensee, when Disposing of any Licensed Product, shall Dispose of the Licensed Product in compliance with
all applicable governmental laws, rules, and regulations. Licensee shall keep Carnegie Mellon fully informed of, and shall use
commercially reasonable efforts to resolve, any complaint by a governmental body relevant to the Licensed Products, except for
complaints subject to Section 22 (Infringement) of this Agreement.


 


2.6.
[* * *].


 


2.7.
It is a condition of the continued existence of this Agreement that Creators of the Licensed Technology having any rights under
Carnegie Mellon’s Intellectual Property Policy, who are or become (in the period two years after the Effective Date) Owners
(other than through distribution of Shares received by Carnegie Mellon or purchase of Shares after a public offering or the sale
of substantially all of the assets of Licensee to a third party), full-time or substantially full-time employees, full-time or
substantially full-time consultants, or full-time or substantially full-time subcontractors of or to Licensee, before assuming
such status regarding Licensee, have executed and delivered to Carnegie Mellon an assignment to Carnegie Mellon, in the form of
Attachment B of this Agreement, of their rights as Creators to receive any amounts that would otherwise thereafter be due to them
under Carnegie Mellon’s Intellectual Property Policy, under or by reason of implementation of this Agreement. Licensee will
be required to provide to Carnegie Mellon a signed proof of waiver from any such Creator, who occupies the status of Owner or
full-time or substantially full-time employee, full-time or substantially full-time consultant or full-time or substantially full-time
subcontractor of Licensee at any time during the period commencing on or before the Effective Date and ending two years thereafter.
Such information will be provided within five (5) days of the execution of this Agreement and will be updated within five (5)
days of any changes in accordance with Section 23 (Notices).


 


2.8.
This Agreement is subject to any government purpose license rights under 35 USC §202 (c) (4) and any march-in rights of the
United States of America under 35 USC §203.


 






     


     


    

 


3.
Term of this Agreement


 


The
term of this Agreement shall conclude at the end of twenty (20) years from the Effective Date, or on the expiration date of the
last-to-expire Patent, whichever comes later, unless otherwise terminated pursuant to another provision of this Agreement; except
in the case where this Agreement is otherwise terminated earlier pursuant to another provision of this Agreement, at the expiration
of the term of this Agreement, the rights and licenses granted to Licensee by Carnegie Mellon pursuant to Section 2 hereof shall
thereafter survive in perpetuity, subject to and contingent upon Licensee’s compliance with the obligations specified in
Section 16 (Indemnification), and 21 (Dispute Resolution) hereof.


 


4.
Carnegie Mellon Shares


 


4.1.
As partial consideration for the license rights granted by Carnegie Mellon herein: (a) within thirty (30) days from the Effective
Date, Licensee will issue and deliver to Carnegie Mellon 820,000 of shares of common stock of Licensee (the “Common Stock”),
which Common Stock shall constitute eight and two tenths percent (8.2%) of the then fully-diluted capitalization of Licensee,
and (b) Licensee will issue a warrant to Carnegie Mellon (substantially in the form attached hereto as Attachment C of this Agreement),
exercisable only upon the earlier of (i) the day that Licensee receives cumulative capital funding and/or cumulative Revenues
equal to the sum of Two Million Dollars (U.S. $2,000,000) or (ii) thirty (30) days prior to any Change of Control Event that provides
for the issuance of Shares, for a number of shares of Common Stock sufficient such that when added to the shares of Common Stock
issued to Carnegie Mellon pursuant to clause (a) of this Section 4.1 Carnegie Mellon holds in the aggregate an amount equal to
eight and two tenths percent (8.2%) of the fully-diluted capitalization of Licensee; provided, however, that for the purposes
of calculating the above eight and two tenths percent (8.2%) only the first Two Million Dollars (U.S. $2,000,000) of capital funding
shall be considered in the determination of Licensee’s fully-diluted capitalization.


 


4.2.
Subject to the execution and delivery by Carnegie Mellon to the Company, and agreement to be bound by the obligations in, all
transaction documents entered into by other purchasers participating in the applicable issuance of equity securities, including
a purchase agreement, an investor rights agreement and other ancillary agreements, with customary representations and warranties
and transfer restrictions (including, without limitation, a 180-day lock-up agreement in connection with an Initial Public Offering),
prior to a Qualified IPO or a Qualified Sale, Carnegie Mellon shall have preemptive rights with respect to additional issuances
of equity securities (or securities convertible or exchangeable into equity securities) (“Equity Securities”),
including without limitation issuances of Equity Securities to Licensee employees in exchange for cash, the effect of which will
be that Carnegie Mellon shall have the right to subscribe for additional Equity Securities so as to maintain its eight and two
tenths percent (8.2%) equity interest without dilution or diminution.


 


4.3.
In any public offering of securities conducted by Licensee, which includes Shares held by Owners, Carnegie Mellon shall be entitled
to participate on a pro rata basis to the same extent as such selling Owners (or any permitted transferee of such selling Owners)
and on terms and conditions no less favorable to Carnegie Mellon than those provided to such selling Owners (or such permitted
transferee); provided, however, that the rights contained in this Section 4.3 shall be subject to any future restrictions imposed
on Owners by future financing or related transaction documents, or reasonable requests by Licensee’s underwriters in connection
with any such public offering.


 






     


     


    

 


4.4.
Carnegie Mellon shall have the right of co-sale such that, if another Owner desires to sell all or any part of his or its Shares,
now owned or hereinafter acquired, any such sale of Shares will be subject to the following rights of co-sale. Carnegie Mellon
shall have the right to sell to the purchaser of the stock, on the same terms and conditions, an amount of Shares equal to the
number of Shares then owned by Carnegie Mellon equal to (i) the percentage of Carnegie Mellon Shares times the number of Shares
to be sold or (ii) at the option of Carnegie Mellon, a lesser number of Shares (“Co-Sale Right”). The effect
of this Co-Sale Right will be to equate, on a percentage ownership basis, the number of Shares sold by the selling Owner and each
of the other Owners, which may prevent the selling Owner from selling the number of Shares which he or it originally intended
to sell.


 


4.5.
Notwithstanding the foregoing, the provisions of Section 4.4 shall not apply to any sale by a Owner in an underwritten public
offering under an effective registration statement under the Securities Act of 1933, as amended.


 


5.
Minimum Performance Requirements


 


5.1.
Licensee shall use its best efforts to effect introduction of Licensed Technology into the commercial market as soon as possible;
thereafter, until the expiration of this Agreement, Licensee shall keep Licensed Technology reasonably available to the public.
For the purpose of clarity, “best efforts” means Licensee shall achieve the milestones listed in Section 5.2 below.


 


5.2.
Licensee shall achieve the following milestones:


 


		(i)	Submission
                                         of a business plan to Carnegie Mellon, by [* * *]



 


		(ii)	Initial
                                         funding of $250,000 (including grants) attained by [* * *]



 


		(iii)	Initial
                                         product specification developed and preliminary market testing for a Licensed Product
                                         for each invention listed in Attachment A completed by [* * *]



 


		(iv)	Minimum
                                         development of a Licensed Product during the periods specified below:



 


a)
From Effective Date until Year ending [* * *] = [* * *] in financing, and [* * *] 


b)
From Effective Date until Year ending [* * *] = [* * *] in financing, and [* * *] 


c)
From Effective Date until Year ending [* * *] = [* * *] in financing, [* * *], and a [* * *]


 






     


     


    

 





		(v)	Minimum
                                         Revenues during the periods specified below:


 


a)
From Effective Date until Year ending [* * *] = [* * *] 


b)
From Effective Date until Year ending [* * *] = [* * *]


 


5.3.
Licensee’s failure to perform in accordance with Sections 5.1 or 5.2 herein shall be grounds for Carnegie Mellon to a) terminate
this Agreement pursuant to Section 11.2 herein, b) terminate the license granted to any invention listed in Attachment A, or b)
terminate the exclusivity of the license to any invention listed in Attachment A (by amending the word “exclusive”
in the related license grant to read “non-exclusive”). However, Licensee may obtain one [* * *] extension to meet
each milestone by payment of [* * *] to Carnegie Mellon.


 


6.
Royalties and Payment Terms


 


6.1.
Royalties payable by Licensee to Carnegie Mellon shall be [* * *] of Net Sales. However, no Royalties from Dispositions of Licensed
Products by Licensee (but not any of its sublicensees) under this Section shall be due and payable to Carnegie Mellon for a period
of three (3) years following the Effective Date or until the closing of a Change of Control Event, whichever may occur sooner.
In the event that Licensee is legally required to pay bona fide royalties to a third party(ies) with respect to any Disposition
of a Licensed Product for which Licensee is also legally required to pay Royalties to Carnegie Mellon under this Agreement, then
Licensee shall be entitled to deduct fifty percent (50%) of such royalties paid to such third party(ies) with respect to that
Disposition of a Licensed Product from the Royalties due to Carnegie Mellon under this Agreement for that Disposition of a Licensed
Product; provided that such Royalties due to Carnegie Mellon shall in no event be less than [* * *] of Net Sales.


 


6.2.
Licensee shall pay to Carnegie Mellon [* * *] of Sublicense Fees.


 


6.3.
Royalties and Sublicense Fees payable to Carnegie Mellon shall be paid by Licensee to Carnegie Mellon, as set forth in this Section
6, for each Fiscal Quarter within sixty (60) days after the end of such Fiscal Quarter, until this Agreement expires or is terminated
in accordance with the terms of this Agreement. If this Agreement terminates before the end of a Fiscal Quarter, the payment for
the terminal fractional portion of a Fiscal Quarter shall be made within ninety (90) days after the date of termination of this
Agreement. All Royalties and other amounts payable hereunder shall be paid in U.S. Dollars and shall be made by wire transfer
to Carnegie Mellon’s account No. [* * *], or by Licensee’s check sent in accordance with Section 22 (Notices).


 


6.4.
All amounts payable hereunder which are overdue shall bear interest until paid at a rate equal to the Prime Rate in effect at
the date such amounts were due plus four percent (4%) per annum, but in no event to exceed the maximum rate of interest permitted
by applicable law. This provision for interest shall not be construed as a waiver of any rights Carnegie Mellon has as a result
of Licensee’s failure to make timely payment of any amounts.


 


7.
Reports and Audits


 


7.1.
Licensee shall report Quarterly to Carnegie Mellon Net Sales and Revenues and Sublicense Fees which are subject to Royalty and
other payments within sixty (60) days of the end of the relevant Quarter.


 






     


     


    

 


7.2.
Licensee shall maintain accurate books and records such that the Royalties and other amounts due and payable hereunder can be
easily ascertained. Such books and records shall be maintained at Licensee’s principal place of business. Licensee shall
make available Licensee’s books and records for audit by Carnegie Mellon or its designee, and Licensee agrees to cooperate
fully in any such audit, provided that Carnegie Mellon and its designee (if any) agree to protect the confidentiality of the information
as to the customers of Licensee. Any such audit shall not be more frequent than annually. In the event of any deficiency in payment,
in addition to paying the deficiency, if the audit determines that any amounts paid to Carnegie Mellon were deficient by more
than five percent (5%), Licensee shall also pay the costs of the audit, all within thirty (30) days following written notice of
such deficiency.


 


7.3.
Licensee shall report to Carnegie Mellon the date of the first commercial Disposition of a Licensed Product within sixty (60)
days of occurrence in each country.


 


7.4.
Within sixty (60) days after the end of each of Licensee’s fiscal years, Licensee shall furnish Carnegie Mellon with a written
report on the progress of its efforts during the immediately preceding fiscal year to develop and commercialize Licensed Products.
The report shall also contain a discussion of intended efforts and sales projections for the year in which the report is submitted,
as outlined in Attachment D.


 


7.5.
Within sixty (60) days after the end of each of Licensee’s fiscal years, Licensee shall provide Carnegie Mellon with Licensee’s
financial statements for the immediately preceding fiscal year (including, at a minimum, an income statement, a statement of cash
flows, and a balance sheet) that have been certified by Licensee’s treasurer, chief financial officer, or an independent
auditor.


 


7.6.
Carnegie Mellon shall keep confidential, not disclose to any third party and not use for any purpose other than monitoring Licensee’s
performance under this Agreement and/or enforcing its rights under this Agreement, the terms of this Agreement and all reports,
financial statements, documents and other confidential or proprietary information of Licensee provided to Carnegie Mellon’s
Center for Technology Transfer and Enterprise Creation by Licensee under this Agreement; provided, however, that Carnegie Mellon
may include in its annual reports totals derived from information received from Licensee (without attribution to Licensee) that
show revenues generated by the Licensed Technology; and provided further that the non-disclosure and non-use obligations shall
not apply to any information that (a) is or becomes part of the public domain other than by breach by Carnegie Mellon of this
Section 7.6, or (b) is required to be disclosed by Carnegie Mellon pursuant to interrogatories, requests for information or documents,
subpoena, civil investigative demand issued by a court or governmental agency or as otherwise required by law, provided that Carnegie
Mellon shall limit the disclosure to such information that it is legally required to disclose. Notwithstanding the foregoing,
to the extent that it is reasonably necessary as determined by Carnegie Mellon, Carnegie Mellon may disclose information it is
otherwise obligated under this Section 7.6 not to disclose in confidence to its lawyers, accountants, auditors, trustees, inventors,
funding sources, and financial advisors.


 






     


     


    

 


8.
Improvements


 


8.1.
[* * *].


 


8.2.
Licensee will own all of the right, title and interest (including patents, copyrights, mask work rights, trade secrets and any
other intellectual property rights, but excluding Patents) in and to the results of the collaboration between the parties that
are developed solely by Licensee employees or agents, when acting as such.


 


8.3.
Carnegie Mellon will own all of the right, title and interest (including patents, Patents, copyrights, Copyrights, mask work rights,
trade secrets and any other intellectual property rights) in and to the results of the collaboration between the parties that
are developed solely by Carnegie Mellon employees or agents, when acting as such.


 


8.4.
If any other intellectual property rights are developed jointly by employees or agents of Carnegie Mellon and Licensee, each when
acting as such, which would not constitute a Patent or Licensed Technology and which are not subject to another agreement between
Carnegie Mellon and Licensee, Carnegie Mellon and Licensee shall jointly own (without any duty to account to the other for profits)
all right, title and interest (including patents, copyrights, mask work rights, trade secrets, and other intellectual property
rights) in and to the results of such joint development. If any technology or patentable invention which would not constitute
a Patent or Licensed Technology arises out of such joint development by employees or agents of Carnegie Mellon and Licensee, each
when acting as such, Carnegie Mellon and Licensee will engage in good faith efforts to mutually agree on whether and how to pursue
patent, copyright or mask work protection of the invention in the U.S. and elsewhere.


 


8.5.
[* * *].


 


9.
Patents and Other Intellectual Property


 


9.1.
Intellectual property rights to Licensed Technology such as Patent(s), patent(s), and Copyrights which may be obtainable will
remain the property of Carnegie Mellon. Trademarks existing on the Effective Date belong to Carnegie Mellon.


 


9.2.
Within thirty (30) days of the Effective Date, Licensee shall make a one-time payment to Carnegie Mellon of fifty-three thousand
seven hundred ninety-two dollars and fifty cents (US$53,792.50) for patenting and other intellectual property protection costs
incurred by Carnegie Mellon prior to the Effective Date and relating to the Licensed Technology. Thereafter, Licensee shall pay
for or reimburse Carnegie Mellon for all fees and expenses related to future Patent expenses, within thirty (30) days of receipt
of each notification or bill.


 


9.3.
Carnegie Mellon has applied for, and/or will apply for and prosecute Patent coverage in any country if so requested by Licensee,
at Licensee’s sole expense, for any and all Patents to the extent that such protection is reasonably obtainable.


 


9.4.
Carnegie Mellon may, at its option and sole discretion and at its own expense pursue patent, copyright and/or trademark rights
for Licensed Technology in any country for which coverage has not been requested by Licensee in accordance with Subsection 9.3
herein. If Licensee does not reimburse Carnegie Mellon for such amounts within thirty (30) days of the receipt of each notification
or bill therefor, then Licensee shall have no rights relating to same in that country.


 






     


     


    

 


9.5.
No less than forty-five (45) days before instituting any legal proceeding contesting the validity or enforceability or use of
a license granted hereunder, Licensee shall give written notice to Carnegie Mellon of its intention to bring such a challenge
and a detailed description of the legal and factual basis for such a challenge to preserve Carnegie Mellon’s ability to
have any such challenge proceed in a forum convenient for Carnegie Mellon and to assist the parties in seeking to resolve the
dispute without the need for judicial action.


 


9.6.
In prosecution and maintenance of the Patents, Carnegie Mellon shall provide to Licensee drafts of any responses to advisory actions,
office actions, amendments or the like in advance for Licensee to review and comment. Carnegie Mellon shall consider in good faith
all comments made by Licensee.


 


10.
Markings, Trademarks and Trade Names


 


10.1.
If practicable, Licensee shall include in all sales, marketing literature and invoices relating to Licensed Product, a statement
to the effect that “this product or portions thereof is manufactured under license from Carnegie Mellon University.”


 


10.2.
If a Licensed Product falls within the scope of one or more claims of a pending application within Patents, and if required by
law, Licensee shall mark each Licensed Product and/or packaging therefor, any time prior to sale, with Patent Pending”,
and, if a Licensed Product falls within the scope of one or more claims of an unexpired patent within Patents, Licensee shall
mark each Licensed Product and/or packaging therefor any time prior to sale, with the applicable patent number or numbers in accordance
with the applicable laws of the countries in which the materials are intended to be used. Licensee may use virtual marking where
appropriate.


 


10.3.
Licensee acknowledges that the title to the Technology (including Copyright) shall remain with Carnegie Mellon.


 


10.4.
Licensee acknowledges that it does not have any ownership rights or any title whatsoever in or to the Technology, any Carnegie
Mellon trade name or in or to any of Carnegie Mellon’s trademarks, except as provided under this Agreement. Licensee shall
neither register nor use any Carnegie Mellon trademarks or trade names. Any reference by Licensee to Carnegie Mellon beyond the
above or beyond as otherwise provided in this Agreement may only be done with express written permission of Carnegie Mellon’s
Director of the Center for Technology Transfer and Enterprise Creation.


 


11.
Termination


 


11.1.
In the event that Licensee defaults in the payment in full of any amount required to be paid under this Agreement on the date
such payment is due, in addition to utilizing any other legal and/or equitable remedies, and fails to cure such default within
thirty (30) days after written notice of such default from Carnegie Mellon, Carnegie Mellon shall have the right by written notice
to Licensee to (a) terminate the exclusivity, if any, of any license hereunder (by amending the word “exclusive” in
the related license grant to read “non-exclusive”) without any reduction in any of the payments due from Licensee
or (b) terminate this Agreement. In addition to the foregoing, in the event that (a) Licensee shall make or offer to make any
arrangement or composition with or for the benefit of its creditors, or (b) Licensee ceases or threatens to cease to carry on
its business, or (c) Licensee is or becomes unable to pay its debts as they become due, or (d) Licensee commits any act of insolvency
or bankruptcy, or (e) a petition or resolution for the making of an administration order or for the bankruptcy, winding-up or
dissolution of Licensee is presented or passed, or (f) Licensee files a voluntary petition in bankruptcy or insolvency, or (g)
a receiver or administrator takes possession of or is appointed over the whole or any part of the assets of Licensee, or (h) any
analogous procedure is commenced against or by Licensee in any jurisdiction, Carnegie Mellon shall have the right by written notice
to Licensee to terminate this Agreement.


 






     


     


    

 


11.2.
In the event that either party to this Agreement defaults in the performance of any of its obligations hereunder (other than any
of the defaults or events referred to in Section 11.1. hereof) and fails to cure such default within thirty (30) days after written
notice of such default from such other party, the other party shall have the right by written notice to the defaulting party to
terminate this Agreement.


 


11.3.
In the event that any of (a) Licensee, or (b) an Affiliate of Licensee, or (c) a third party acting on behalf of Licensee or one
of its Affiliates, challenges or disputes the validity or enforceability of any intellectual property rights licensed hereunder
in any judicial or administrative proceeding in a court or agency of competent jurisdiction, Carnegie Mellon may, at its option
and sole discretion, terminate the license or terminate exclusivity as to such challenged intellectual property by notice in writing
to Licensee.


 


11.4.
The Royalty rates and other amounts stated herein have been negotiated with the understanding that no court has made any determination
as to the validity or enforceability of any Patent specifically claiming any of the Licensed Technology or whether any of Licensee’s
products infringe any claim of any Patent. Licensee desires to obtain a license under the terms stated herein, without regard
to the lack of such adjudication. In the event that Licensee or any Affiliate of Licensee challenges the validity or enforceability
of any Patent in a court or agency of competent jurisdiction, or commences a judicial proceeding involving whether any of its
products based on the Licensed Technology infringe any Patents or would infringe a Patent in the absence of this license, and
such validity, enforceability or infringement is upheld in any such judicial or administrative proceeding (including a reexamination
that results in issuance of amended claims), Royalties due and payable under Section 6.1 herein shall, effective immediately as
of the date such validity, enforceability or infringement is upheld, increase to five and four tenths percent (5.4%) to take into
account the additional certainty regarding Carnegie Mellon’s rights provided by such a resolution and to compensate Carnegie
Mellon for the burden and expense of such challenge.


 


11.5.
The termination of this Agreement pursuant to this Section 11 or pursuant to Section 3 hereof shall not terminate (a) the obligation
of Licensee to pay any amounts which have accrued or would otherwise be required to be paid by Licensee under the terms of this
Agreement, and (b) the obligations of Licensee under Sections 7 (Reports and Audits), 9 (Patents and Other Intellectual Property),
11 (Termination), 12 (Taxes), 15 (Confidentiality and Trade Secrets), 16 (Indemnification), 17 (Insurance), 21 (Dispute Resolution),
and 22 (Infringement) hereunder.


 






     


     


    

 


11.6.
Licensee may terminate this Agreement upon thirty (30) days advance written notice to Carnegie Mellon and payment to Carnegie
Mellon in accordance with the following schedule:


 


	Termination
    Date	Termination
    Payment Amount
	Effective
    Date to December 31, 2019	$[*
    * *] USD
	January
    1, 2020 to December 31, 2020	$[*
    * *] USD
	January
    1, 2021 to December 31, 2021	$[*
    * *] USD
	January
    1, 2022 to December 31, 2022	$[*
    * *] USD
	January
    1, 2023 to December 31, 2023	$[*
    * *] USD
	January
    1, 2024 to December 31, 2024	$[*
    * *] USD
	January
    1, 2025 to December 31, 2038	$[*
    * *] USD


 


The
termination fee is in addition to any amounts otherwise required to be paid by Licensee under the terms of this Agreement. However,
Licensee is only required to pay the termination fee if, at the time of termination, a Patent in the United States contains a
valid claim, a valid claim being: (i) a claim of a pending patent application included within the Patents that has been pending
without grant of patent for no greater than five (5) years from the original priority date of the claim; and/or (ii) a claim of
an issued and unexpired patent included within the Patents that has not been revoked or held unenforceable or invalid by a decision
of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
or which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise.


 


11.7.
Upon termination of this Agreement for any reason and as requested in writing by Sublicensee within sixty (60) days following
termination, Carnegie Mellon shall within ninety (90) days receipt of the written request, negotiate in good faith with Sublicensee
a direct license with Carnegie Mellon for the Technology and/or Patents; provided Sublicensee is not in breach of the applicable
sublicense and whose sublicense was not granted in violation of this Agreement.


 


12.
Taxes


 


Licensee
shall pay all taxes which may be assessed or levied on, or on account of, the Licensed Products made or Disposed of and all taxes
assessed or levied on, or on account of, the amounts payable to, or for the account of, Carnegie Mellon under this Agreement (other
than Carnegie Mellon’s U.S. federal, state or local income or franchise taxes).


 


13.
NO WARRANTY; LIMITATION AS TO TYPES OF DAMAGES


 


ANY
AND ALL INFORMATION, MATERIALS, SERVICES, INTELLECTUAL PROPERTY AND OTHER PROPERTY AND RIGHTS GRANTED AND/OR PROVIDED BY CARNEGIE
MELLON PURSUANT TO THIS AGREEMENT, INCLUDING THE LICENSED TECHNOLOGY ARE GRANTED AND/OR PROVIDED ON AN “AS IS” BASIS.
CARNEGIE MELLON MAKES NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER, AND ALL SUCH WARRANTIES, INCLUDING
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARE EXPRESSLY DISCLAIMED. WITHOUT LIMITING THE GENERALITY
OF THE FOREGOING, CARNEGIE MELLON DOES NOT MAKE ANY WARRANTY OF ANY KIND RELATING TO EXCLUSIVITY, INFORMATIONAL CONTENT, ERROR-FREE
OPERATION, RESULTS TO BE OBTAINED FROM USE, FREEDOM FROM PATENT, TRADEMARK AND COPYRIGHT INFRINGEMENT AND/OR FREEDOM FROM THEFT
OF TRADE SECRETS. LICENSEE IS PROHIBITED FROM MAKING ANY EXPRESS OR IMPLIED WARRANTY TO ANY THIRD PARTY ON BEHALF OF CARNEGIE
MELLON RELATING TO ANY MATTER, INCLUDING THE APPLICATION OF OR THE RESULTS TO BE OBTAINED FROM THE INFORMATION, MATERIALS, SERVICES,
INTELLECTUAL PROPERTY OR OTHER PROPERTY OR RIGHTS, INCLUDING THE LICENSED TECHNOLOGY GRANTED AND/OR PROVIDED BY CARNEGIE MELLON
PURSUANT TO THIS AGREEMENT


 






     


     


    

 


CARNEGIE
MELLON SHALL NOT BE LIABLE TO LICENSEE OR ANY THIRD PARTY FOR ANY REASON WHATSOEVER ARISING OUT OF OR RELATING TO THIS AGREEMENT
(INCLUDING ANY BREACH OF THIS AGREEMENT) FOR LOSS OF PROFITS OR FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN
IF CARNEGIE MELLON HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR HAS OR GAINS KNOWLEDGE OF THE EXISTENCE OF SUCH DAMAGES.


 


14.
Costs


 


All
costs and expenses incurred by Licensee in carrying out Licensee’s obligations under this Agreement shall be paid by Licensee,
and Licensee shall not be entitled to reimbursement from Royalties hereunder or otherwise therefor from Carnegie Mellon. Licensee
and its sublicensees shall possess or obtain at its own expense all necessary licenses and permits and shall comply with all laws,
ordinances, rules or regulations affecting the exportation or Disposition of Licensed Products, Licensed Technology and/or Derivatives.


 


15.
Confidentiality


 


15.1.
“Confidential Information” shall mean any information relating to the Licensed Technology, the terms of this
Agreement (as from time to time amended), Patents, covered by this Agreement or information disclosed to Licensee in the manner
set forth hereinafter. All such information shall be Confidential Information, including information disclosed to Licensee prior
to the Effective Date, unless such information (a) was already in Licensee’s possession prior to the disclosure thereof
by Carnegie Mellon as provided in subsection 15.1(1) hereof, (b) has been published or is published hereafter, unless such publication
is a breach of this Agreement, (c) is received by Licensee from a third party not under an obligation of confidentiality with
respect thereto, or (d) is independently developed by Licensee.


 


(1)
In the event that such information shall be established to have been known to Licensee prior to the disclosure thereof by Carnegie
Mellon by reference to any publication thereof by Licensee or by reference to any internal writing or other business record maintained
by Licensee in the ordinary course of business, such information shall not be deemed to be Confidential Information for purposes
of this Agreement following notification to Carnegie Mellon of such fact.


 






     


     


    

 


(2)
With respect to any information not related to the Licensed Technology which is sought by Carnegie Mellon to be Confidential Information
subject to this Agreement, Carnegie Mellon shall mark such information as “Confidential” prior to disclosing it to
Licensee.


 


(3)
With respect to any oral communication not related to the Licensed Technology which is deemed by Carnegie Mellon to be Confidential
Information subject to this Agreement, Carnegie Mellon shall notify Licensee of such fact and within thirty (30) days thereafter
Carnegie Mellon shall send a memorandum to Licensee outlining the information deemed to be Confidential Information.


 


15.2.
Licensee shall maintain in confidence and shall not disclose to any person not a party hereto, nor shall Licensee use or exploit
in any way without Carnegie Mellon’s written agreement, any Confidential Information until three (3) years after the later
of the date of termination of this Agreement or the end of the term of the last to expire Patent, unless such information ceases
to be Confidential Information prior to the end of such period through no fault of Licensee or Licensee and Carnegie Mellon enter
into an agreement authorizing same. Notwithstanding the foregoing, Licensee may disclose Confidential Information to potential
investors of Licensee strictly on a need-to-know basis as is necessary for such potential investor to make an investment decision
in Licensee.


 


15.3.
Licensee shall exercise all reasonable precautions to prevent the disclosure of Confidential Information by its employees or representatives,
and in any event shall maintain with respect to such Confidential Information a standard of care which is no less than that standard
which Licensee maintains to prevent the disclosure of its own confidential information but no less than a reasonable standard
of care. Notwithstanding the foregoing, Licensee may disclose Confidential Information to potential investors of Licensee strictly
on a need-to-know basis as is necessary for such potential investor to make an investment decision in Licensee.


 


15.4.
Upon termination of this Agreement under Sections 11.1, 11.2, 11.3, or 11.6, Licensee agrees to return promptly to Carnegie Mellon,
without copying, all originals and copies of all materials (other than this Agreement) containing any Confidential Information.


 


16.
Indemnification


 


Licensee
and its sublicensees shall defend, indemnify, and hold harmless Carnegie Mellon and its trustees, officers, employees, attorneys
and agents from and against any liability, damage, loss or expense (including attorneys’ fees and expenses) incurred by
or imposed upon any of Carnegie Mellon and/or its trustees, officers, employees, attorneys and agents in connection with any claim,
suit, action or demand arising out of or relating to any exercise of any right or license granted or provided to Licensee and/or
its sublicensees or any failure to perform any obligation of Licensee and/or any sublicensees under this Agreement and/or any
sublicense, including any Disposition of Licensed Product(s), under any theory of liability (including without limitation, actions
in the form of tort, warranty, or strict liability, or violation of any law, and regardless of whether such action has any factual
basis).


 






     


     


    

 


17.
Insurance


 


Licensee
and each sublicensee shall, at its own expense, obtain prior to the first commercial sale of a Licensed Product, clinical trial,
or use in humans, and maintain throughout the term of this Agreement, commercial general liability insurance with a limit of not
less than [* * *] per occurrence and [* * *] aggregate for products liability and completed operations from an insurance company(ies)
having a financial rating from AM Best or similar rating service of at least an “A-”. Carnegie Mellon shall be identified
and named as an additional insured on such insurance policy(ies). Licensee agrees to provide and to cause each sublicensee to
provide Carnegie Mellon with evidence of such insurance upon the execution of this Agreement (and thereafter from time to time
as Carnegie Mellon may request).


 


18.
No Acquiescence


 


No
acquiescence in any breach of this Agreement by either party shall operate to excuse any subsequent or prior breach.


 


19.
Entire Agreement


 


This
Agreement supersedes all previous agreements relating to the subject matter hereof, whether oral or in a writing, and constitutes
the entire agreement of the parties hereto relating to the subject matter hereof and may not be amended or altered in any respect
except in a writing executed by the parties.


 


20.
Governing Law


 


This
Agreement shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Pennsylvania, without
regard to conflict of law principles in that or any other jurisdiction.


 


21.
Dispute Resolution


 


All
claims and/or controversies of every kind and nature arising out of or relating to this Agreement, including any questions concerning
its existence, negotiation, validity, meaning, performance, non-performance, breach, continuance or termination shall be settled
(a) at Carnegie Mellon’s election, by binding arbitration administered by the American Arbitration Association (“AAA”)
in accordance with its Commercial Arbitration Rules and, in such case (i) the arbitration proceedings shall be conducted before
a panel of three arbitrators, with each party selecting one disinterested arbitrator from a list submitted by the AAA and the
two disinterested arbitrators selecting a third arbitrator from the list, (ii) each party shall bear its own cost of arbitration,
(iii) all arbitration hearings shall be conducted in Allegheny County, Pennsylvania, and (iv) the provisions hereof shall be a
complete defense to any suit, action or proceeding instituted in any federal, state or local court of before any administrative
tribunal with respect to any claim or controversy arising out of or relating to this Agreement and which is arbitrable as provided
in this Agreement, provided that either party may seek injunctive relief in a court of law or equity to assert, protect or enforce
its rights in any intellectual property and/or confidential or proprietary information as described in this Agreement, or (b)
in the event that Carnegie Mellon does not elect binding arbitration as permitted in point (a) above, exclusively in the U.S.
District Court for the Western District of Pennsylvania or, if such Court does not have jurisdiction, in any court of general
jurisdiction in Allegheny County, Pennsylvania and each party consents to the exclusive jurisdiction of any such courts and waives
any objection which such party may have to the laying of venue in any such courts.


 






     


     


    

 


22.
Infringement


 


22.1.
So long as Licensee remains the exclusive licensee of any of the Patents in the Field of Use, Licensee shall have the right during
the term of this Agreement to commence an action for infringement of any of those Patents against any third party for any infringement
occurring within the Field of Use, provided that Licensee shall provide Carnegie Mellon sixty (60) days’ prior written notice
of such infringement and of Licensee’s intent to file such action. Carnegie Mellon shall have the right at its own expense
(subject to being reimbursed from any settlement amount or proceeds as provided herein) to appear in such action by counsel of
its own selection. If required by the jurisdictional laws of the forum that any such action be prosecuted in the name of the owner
of the Patent or that Carnegie Mellon be joined as a party, Carnegie Mellon shall appear; except that (a) if such appearance could
subject Carnegie Mellon to any unrelated action or claim of a third party or Licensee in that or any other jurisdiction, then
Carnegie Mellon shall have the right to decline such appearance if Carnegie Mellon may legally do so in the opinions of external
legal counsels for both Carnegie Mellon and Licensee; and (b) Carnegie Mellon shall have no obligation to appear, if external
legal counsels for both Carnegie Mellon and Licensee agree that Carnegie Mellon has no obligation to appear, if the defendant
in such action is Marvell Technology Group, Inc., or any direct or indirect subsidiary thereof, or any successor thereto (collectively,
a “Marvell Entity”), or if the defendant in such action is accused of infringement as a result of the manufacture,
use, importation into the United States, sale, offer of sale, or other disposition of products or processes sold or provided directly
or indirectly by a Marvell Entity. Licensee shall hold Carnegie Mellon harmless from, and indemnify Carnegie Mellon against any
liability, damage, loss, or expense that Carnegie Mellon suffers or incurs, including Carnegie Mellon’s attorneys’
fees and expenses, in connection with, in consequence of or resulting from such action, and all liability, damage, loss, or expense
suffered or incurred by Carnegie Mellon in connection with, in consequence of or resulting from such action, including reasonable
compensation for the time of any Carnegie Mellon personnel, shall be paid by Licensee as the same is incurred by Carnegie Mellon.
Settlement of any action brought by Licensee shall require the consent of Carnegie Mellon and any settlement amount or recovery
for damages shall be applied as follows: (a) first, to reimburse the parties for their unreimbursed expenses in connection with
the litigation; and (b) second, Carnegie Mellon shall receive compensation for unreimbursed time of any Carnegie Mellon personnel
involved in the action; and (c) third, Carnegie Mellon shall receive the following percentage of the monies remaining: ten percent
(10%).


 


22.2.
In the event that Licensee is unsuccessful in persuading an alleged infringer to desist or fails to initiate any infringement
action contemplated by Section 22.1 within a reasonable time after Licensee first becomes aware of the basis for such action,
Carnegie Mellon shall have the right, in its sole discretion, to prosecute such infringement action at its sole expense, and any
settlement amount or recovery shall belong to Carnegie Mellon.


 






     


     


    

 


22.3.
Notwithstanding the pendency of any infringement (or other) claim or action by or against Licensee, Licensee shall have no right
to terminate or suspend (or escrow) payment of any amounts required to be paid to Carnegie Mellon pursuant to this Agreement.


 


23.
Notices


 


Any
notice under any of the provisions of this Agreement shall be deemed given when (a) personally delivered, or (b) sent prepaid
by nationally recognized overnight carrier, or (c) deposited in the mail, postage prepaid, registered or certified first class
mail, and in the case of (b) or (c), when addressed to the applicable party at the address stated on the signature page hereof,
or such other address as such party shall specify for itself by like notice to other party. Each party shall in the case of (b)
or (c), transmit to the other a facsimile copy or an electronic mail copy of each such notice promptly after sending same by nationally
recognized overnight carrier or depositing same in the mail, as applicable.


 


24.
Assignment


 


Licensee
shall not assign or transfer this Agreement or any interest herein without the prior written consent of Carnegie Mellon; provided
that Licensee can assign this Agreement without such consent in connection with a merger or consolidation of Licensee with or
into another entity, change of control, or sale of all or substantially all of Licensee’s assets that relate to the Licensed
Technology provided that such successor or purchaser shall agree in writing to be bound by the terms of this Agreement prior to
such Assignment. Failure of such assignee to so agree shall be grounds for termination of this Agreement per Section 11.2.


 


25.
Headings


 


The
section headings contained in this Agreement are set forth for the convenience of the parties only, do not form a part of this
Agreement and are not to be considered a part hereof for the purpose of construction or interpretation hereof, or otherwise.


 


26.
Severability


 


If
any provision of this Agreement or portion thereof is determined by a court of competent jurisdiction, or declared under any law,
rule or regulation of any government having jurisdiction over the parties hereto, to be invalid, illegal or otherwise unenforceable,
then such provision will, to the extent permitted by the court or government not be voided but will instead be construed to give
effect to its intent to the maximum extent permissible under applicable law and the remainder of this Agreement will remain in
full force and effect according to its terms.


 


(The
balance of this page is intentionally left blank).


 




     


     


    

 


The
parties hereto have caused this Agreement to be executed by their duly authorized representatives in duplicate counterparts, each
of which shall be deemed to constitute an original, effective as of the Effective Date.


 





	Carnegie Mellon University	 
	 	 
	By:	/s/ Robert A. Wooldridge	 
	 	Robert A. Wooldridge	 
	 	Associate Vice Provost	 
	 	 	 
	Date:	12/17/2018	 




 


Address
for Notices:


 


Carnegie
Mellon University

4615 Forbes Avenue, Suite 302

Pittsburgh, PA 15213

Attention: Associate Vice Provost for Technology Transfer and Enterprise Creation

Email: innovation@cmu.edu

Facsimile: 412-268-7395


 





	NeuBase Therapeutics, Inc.	 
	 	 
	By:	/s/ Dietrich Stephan	 
	 	Name: Dietrich Stephan	 
	 	Title: Chief Executive Officer	 
	 	 	 
	Date:	12/17/2018	 




 


	Address for Notices:	2730 Sidney Street, Suite
    300

    Pittsburgh, PA 15203
	 	 
	Attention:	Dietrich Stephan
	Email:	dstephan@neubasetherapeutics.com





 






     


     


    

 


Attachment
A



Description of Licensed Technology


 


[*
* *]







     


     


    

 


Attachment
B



Assignment Agreement


 


[*
* *]


 


[Signatures
appear on the following page.]


 




     


     


    

 


This
document is executed with the intent to be legally bound hereby.


 


	[* * *]	[* * *]
	 	 
	[* * *]	[* * *]
	 	 
	[* * *]	[* * *]





 






     


     


    

 


Assignment
Agreement


 


[*
* *]


 


This
document is executed with the intent to be legally bound hereby.


 


	[* * *]	[* * *]
	 	 
	[* * *]	[* * *]
	 	 
	[* * *]	[* * *]